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SUMMARY
Conventional dendritic cells (cDCs) are thought
to descend from a DC precursor downstream of
the common myeloid progenitor (CMP). However,
a mouse lymphoid-primed multipotent progenitor
has been shown to generate cDCs following a DC-
specific developmental pathway independent of
monocyte and granulocyte poiesis. Similarly, here
we show that, in humans, a large fraction of multi-
potent lymphoid early progenitors (MLPs) gives rise
to cDCs, in particular the subset known as cDC1,
identified by co-expression of DNGR-1 (CLEC9A)
and CD141 (BDCA-3). Single-cell analysis indicates
that over one-third of MLPs have the potential to effi-
ciently generate cDCs. cDC1s generated from CMPs
or MLPs do not exhibit differences in transcriptome
or phenotype. These results demonstrate an early
imprinting of the cDC lineage in human hematopoie-
sis and highlight the plasticity of developmental
pathways giving rise to human DCs.
INTRODUCTION
Dendritic cells (DCs) are mononuclear phagocytes crucial for
the initiation and regulation of immune responses (Steinman
et al., 2003). They are classically divided into plasmacytoid
DCs (pDCs) and two distinct subsets of conventional DCs
(cDCs), termed cDC1 and cDC2 (Guilliams et al., 2014). The
cDC1 subset constitutes a homogeneous cell population identi-
fied by surface expression of the chemokine receptor XCR1 and
the C-type lectin DNGR-1 (also known as CLEC9A) in both mice
and humans (Crozat et al., 2010; Poulin et al., 2012) and is
defined by its developmental dependence on the transcription
factors BATF3 and IRF8 (Aliberti et al., 2003; Hildner et al.,
2008; Murphy et al., 2016) and the growth factors fms-like tyro-
sine kinase 3 ligand (FLT3L) and granulocyte-macrophage
colony-stimulating factor (GM-CSF) (Ginhoux et al., 2009; Greter
et al., 2012; McKenna et al., 2000; Merad et al., 2013). cDC1s
play a prominent role in cross-presentation of dead cell-associ-
ated antigens and in Th1 and cytotoxic T lymphocyte priming
(Merad et al., 2013). cDC2s are CD11b+ CD172a+, and their dif-
ferentiation depends on IRF4, IRF2, TRAF6, RelB, and RBP-J
transcription factors (Murphy et al., 2016). However, mouse
CD11b+ cDC2s are considerably heterogeneous and include a
subtype whose differentiation depends on KLF4 and induces
Th2-dominated immunity (Tussiwand et al., 2015) as well as gut
CD103+CD11b+ DCs that prominently induce Th17 responses
against pathobionts (Persson et al., 2013; Schlitzer et al., 2013).
Human cDC2s are often identified as HLA-DR+ CD11c+
CD11b+ CD1a+ CD1c+ leukocytes (Caux et al., 1996; Doulatov
et al., 2010) with variable expression of CD14 (Lee et al., 2015).
As for mice, human cDC2 are heterogeneous (Villani et al.,
2017) and, in some cases, can be contaminated with monocyte
progeny that is referred to as ‘‘monocyte-derived DCs’’ and has
a similar surface phenotype (McGovern et al., 2014). Additional
DC subtypes have very recently been described in human blood,
suggesting that DC heterogeneity may be even greater than pre-
viously appreciated (Villani et al., 2017).
DCs are derived from hematopoietic progenitors that are
continuously produced in adult bone marrow by hematopoietic
stem cells (HSCs) (Merad et al., 2013). Early studies indicated
that mouse and human common myeloid progenitors (CMPs)
and common lymphoid progenitors (CLPs) both have the poten-
tial to generate DCs, suggesting that DCs can be generated by
either myelopoiesis or lymphopoiesis (Chicha et al., 2004; Kar-
sunky et al., 2003; Manz et al., 2001; Traver et al., 2000). How-
ever, a fate-mapping experiment using IL7Ra-Cre excluded a
significant contribution of lymphoid progenitors to DC genera-
tion and placed DCs squarely within the myelopoietic branch
(Schlenner et al., 2010). Consistent with that notion, a current
view of DC development is that CMPs give rise to macro-
phage/DC progenitors (MDPs), first identified in mice and then
in humans (Fogg et al., 2006; Lee et al., 2015), which further
differentiate into a commonDCprogenitor (CDP) that is no longer
able to generate monocytes (Lee et al., 2015; Naik et al., 2007;
Onai et al., 2007). In turn, CDPs give rise to circulating pre-DCs
that leave the bone marrow and travel via the blood to seed
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lymphoid and non-lymphoid organs, giving rise to differentiated
DCs (Breton et al., 2015; Ginhoux et al., 2009; Liu et al., 2009;
See et al., 2017). This model of DC development supports
a classical view of hematopoiesis where DC specification
occurs through stepwise loss of multi-lineage potential by
myeloid progenitors (Akashi et al., 2000; Kondo et al., 1997;
Reya et al., 2001).
That model was challenged by a barcoding study that
analyzed the progeny of mouse early lymphoid multipotent
primed progenitors (LMPPs) (Naik et al., 2013). It found that a
large proportion of LMPPs is already imprinted with the potential
to give rise to cDCs independently of monocytes or granulo-
cytes. In addition, a re-analysis of putative mouse MDPs found
that only a very small fraction of cells was truly bi-potential at
the clonal level (Sathe et al., 2014). Altogether, these findings
would seem to indicate that the differentiated mouse cDC pool
might reflect a mixed contribution of MDPs as well as cDC-
imprinted LMPPs, as argued for the pDC lineage (Shortman
et al., 2013). Similarly, in humans, early lympho-myeloid progen-
itors might contribute to DC generation because the multipotent
lymphoid progenitor (MLP; LinCD34+CD38CD45RA+CD10+)
can generate monocytes and HLA-DR+ CD1a+ CD11c+
CD11b+ cells in addition to all lymphoid cells (Doulatov et al.,
2010). However, it remains unclear whether the HLA-DR+
CD1a+ CD11c+ CD11b+ cells generated by human lympho-
myeloid progenitors correspond to bona fide conventional
cDC2 or, instead, reflect a monocyte-derived DC. A more strin-
gent test of the cDC-generating potential of MLPs would be
to assess whether the precursor population can give rise to
cDC1, but this has not been reported. Finally, it is unclear
whether different DCpoietic pathways, if they exist, would give
rise to identical cells. Here we tested the potential of CMPs
versus MLPs to generate human cDC1 and cDC2 cells. We
report that human MLPs can efficiently generate both cDC1s
and cDC2s and that MLP- and CMP-derived cDC1 cells are tran-
scriptionally indistinguishable. These results support a model in
which specification of the cDC lineage can occurs early in hema-
topoiesis in humans and underscore the diversity of hematopoi-
etic decisions giving rise to identical human DCs.
RESULTS
MLPs, CMPs, and GMPs Can Generate cDCs In Vitro and
In Vivo
We have previously shown that unfractionated CD34+ umbilical
cord blood hematopoietic cells can be differentiated in vitro
into CD1a+HLA-DR+CD141+DNGR-1+ cDC1s (Poulin et al.,
2010, 2012) under the aegis of FLT3-L, stem cell factor (SCF),
GM-CSF, and interleukin-4 (IL-4) (FSG4). This culture condition
also allows the differentiation of CD1c+ cDC2 cells and of
CD14+ monocytes (Balan et al., 2014; see below). To analyze
the actual origin of DCs developing in FSG4 cultures, we isolated
different hematopoietic progenitors from human cord blood by
flow cytometry (Figure 1A) following established protocols (Aka-
shi et al., 2000; Chicha et al., 2004; Doulatov et al., 2010) to sort
MLPs, CMPs, and granulocyte/macrophage progenitors
(GMPs), which originate from CMPs but are now known to also
overlap in phenotype with DC precursors (Lee et al., 2015).
MLPs, CMPs, and GMPs all express FLT3 (Doulatov et al.,
2010; Lee et al., 2015), allowing them to respond to FLT3L, a
key pre-requisite for DC differentiation (D’Amico and Wu,
2003). Sorted MLP, CMP, and GMP populations were then
cultured with FSG4, and their DC- and monocyte/macrophage
(mono/mac)-generating potential was analyzed.
We found that MLPs, CMPs, and GMPs were all able to
expand in the FSG4 culture system (Figure S1A) and give
rise to CD141+DNGR-1+ cDC1, CD1a+CD1c+CD14 cDC2,
and CD1aCD14+ mono/macs (Figure 1B). MLPs were efficient
cDC1 progenitors both in terms of percentage and number
of CD141+DNGR-1+ cells generated and were less efficient at
generating cDC2s by the same criteria (Figure 1B). GMPs were
similar in efficiency to MLPs at generating CD141+DNGR-1+
cDC1s, but, intriguingly, CMPs only gave rise to modest
numbers of the same DCs. However, CMPs were as efficient
as MLPs at generating cDC2s and mono/macs in the FSG4 cul-
ture system (Figure 1B). We tested whether the different progen-
itors produced CD141+DNGR-1+ cDC1s with different kinetics.
We found that CMPs, GMPs, and MLPs followed the same
kinetics of differentiation into CD141+DNGR-1+ cDC1s, with a
peak around day 13 in FSG4 (Figure S1B). We then tested
whether the low cDC1-generating potential of CMPs could
be rescued by adding other cytokines to the FSG4 cocktail. All
cytokines tested (IL-6, M-CSF, and G-CSF) extinguished rather
than improved cDC1 generation by CMPs (Figures S1C and
S1D). Finally, we tested the lineage potential of the progenitors
in a more permissive cytokine environment comprising FLT3-L,
SCF, and GM-CSF (FSG) (Figure S1E). This cytokine cocktail en-
ables the differentiation of all DC subsets (cDC1s, cDC2s, and
pDCs) as well as natural killer (NK) cells, monocytes, and granu-
locytes (Lee et al., 2015). Similar to FSG4 cultures, MLP was
the most efficient producer of CD141+DNGR-1+ cDC1s. MLP
was also the only progenitor giving rise to CD56+ NK cells
and to CD303+ pDCs, which were phenotypically distinct from
DNGR-1+ cDC1s (Figures S1E and S1F). In contrast, CMPs
and GMPs were more efficient at generating CD14+ monocytes
and CD66b+ granulocytes (Figure S1E). Altogether, these results
show that MLPs are the most efficient cDC1 progenitors in
various culture settings.
To confirm these results in vivo, we transferred MLPs, CMPs,
and GMPs into non-obese diabetic (NOD)/severe combined
immunodeficiency (SCID)/IL-2Rg-null/Tg(CMV-IL3, CSF2, KIT
ligand [KITLG]) (NSG-SGM3) mice (Billerbeck et al., 2011). Two
weeks later, DC content was analyzed in the bone marrow of re-
cipients. In mice receiving MLPs, CD141+DNGR-1+ cDC1s rep-
resented around 40%of all humanCD45+ cells, whereas, in CMP
recipients, this only reached 10% (Figure 2). In contrast, all pro-
genitors gave rise to a similar low frequency of cDC2s, whereas
GMPs were slightly more efficient than CMPs or MLPs at
generating CD14+ mono/macs. As expected, only MLPs could
generate CD19+ B cells, confirming their lymphoid potential (Fig-
ure S2). Interestingly, MLPs were also the only progenitors able
to give rise to pDCs (Figure S2). Together, these results show
that, at bulk population level, CMPs, GMPs, and MLPs can all
give rise to cDC1s, cDC2s, and mono/macs. CMPs appear to
be biased toward cDC2 and mono/mac generation, whereas
MLPs produce relatively more cDC1s and pDCs both in vitro
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and in vivo. Thus, commitment to the human cDC lineage can
occur in early hematopoietic progenitors with myeloid or lym-
pho-myeloid potential in various experimental settings. Impor-
tantly, MLPs present the best potential for cDC1 and pDC pro-
duction compared with CMPs and GMPs.
Single-Cell Potential of DC Progenitors
To assess the potential of the different progenitors to generate
mononuclear phagocytes at the single-cell level, we set up an
in vitro clonal assay in which single MLPs, GMPs, or CMPs
were isolated and cultured with MS5 stromal cells and FSG4
for 12 days (see Figure S3A for cloning efficiency). The ability
to generate cDC2s and mono/macs did not differ strikingly
among different progenitors and was found in 40%–60% of the
starting populations (Figure 3A). This confirms that DC- and
mono/mac-generating potential is not restricted to a small frac-
tion of contaminating cells in any of the populations. The cloning
efficiency of MLPs was low, which could be due to an effect of
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Figure 1. MLPs, CMPs, and GMPs Can Generate cDCs In Vitro
(A) Gating strategy for human hematopoietic progenitors isolated from umbilical cord blood. Boxes depict gates, and numbers correspond to the percentage of
cells in each gate.
(B) 500 of the indicated progenitor cells isolated according to the gating strategy in (A) were cultured for 12 days in vitro with FLT3-L, IL-4, SCF, and GM-CSF.
CD141+DNGR-1+ cDC1, CD14+CD1a mono/mac, and CD14CD1a+CD1c+ cDC2 progeny were analyzed by flow cytometry. Contour plots depict the gating
strategy used to identify cDC1s, cDC2s, and mono/macs. Graphs show the percentage (left) and numbers (right) of each phagocyte subtype produced and are
the average of three independent cultures. Error bars depict SD. * p < 0.05 (one-way ANOVA). Data are from one experiment representative of at least four
independent experiments.
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combining FSG4 with MS5 without re-optimizing the cytokine
cocktail (unpublished observations). Nevertheless, we found
that more than 50% of the MLPs that generated detectable
clones in MS5 + FSG4 cultures could give rise to cDC1s (Fig-
ure 3A). Moreover, a higher frequency of MLPs could generate
cDC2s than give rise to mono/macs (Figure 3A), and approxi-
mately 37% of single MLPs could differentiate into cDCs
(cDC1s and cDC2s) without generating other myeloid cells (Fig-
ure 3B). This was not the case for the CMPs, which never gener-
ated cDC-only progeny (Figure 3B). These findings suggest that
some hematopoietic progenitors are pre-imprinted with the
potential to give rise to cDCs independently of mono/mac. To
explore this notion, we first focused on the cDC1 subset, which
is more homogeneous than cDC2 (Villani et al., 2017) and, there-
fore, a reliable indicator of cDC commitment. The percentage of
cDC1s generated by individual MLPs or GMPs varied between
1% and 99% (Figure 3C, top; Figure S3B), which suggests the
presence inside of MLP and GMP populations of a spectrum of
cells that have global myeloid potential versus cDC-only poten-
tial. In contrast, the percentage of cDC1s generated by individual
CMPs never reached more than 10%, confirming the absence of
cloneswith a cDC-only potential (Figure 3C, top; Figure S3B).We
then analyzed cDC2 generation efficiency under the same condi-
tions. Similar to cDC1 generation, the percentage of cDC2s
generated by individual MLPs and GMPs varied between 1%
and 99% (Figure 3C, bottom). Interestingly, CMPs were more
efficient on a per-cell basis at generating cDC2s than cDC1s
because some CMP clones could generate more than 50% of
cDC2s. This could suggest that CMPs and MLPs generate
different subsets of cDC2s (Villani et al., 2017), although this
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Figure 2. MLPs, CMPs, and GMPs Can Generate cDCs In Vivo
Irradiated NSG-SGM3 mice were injected intravenously with different human progenitors. Two weeks later, human cDC1, cDC2, and monocyte presence in the
bone marrow was quantitated by flow cytometry. Contour plots and graphs show the generation of CD141+DNGR-1+ cDC1, CD14CD11c+CD1c+ cDC2, and
CD14+CD1c cells by the different progenitors. Each dot represents an individual mouse, bars indicate the mean, and error bars indicate SD. *p < 0.05 (one-way
ANOVA). Data are a pool of two independent experiments.
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was not assessed. Consistent with their cDC-restricted poten-
tial, about 40% of MLPs and GMPs, but no CMPs, expressed,
at the single-cell level, mRNA for IRF8 (Figure 3D), the key
cDC1-specifying factor. In addition, amongMLPs and GMPs ex-
pressing IRF8, 50% of MLPs but only 10% of GMPs had higher
levels of IRF8mRNA per cell (Figure 3D; Figure S3C). Finally, only
5% of MLP clones expressed mRNA for myeloperoxidase
(MPO), a marker of myeloid commitment that was found in
over 50% of GMPs (Figure 3D). Altogether, these data indicate
that early and multipotent lymphoid-primed progenitors such
as MLPs, but not myeloid progenitors such as CMPs, contain
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Figure 3. Single-Cell Potential of DC Pro-
genitors
(A) Single progenitor cells were deposited on a
layer of MS5 cells and cultured for 12 days with
FLT3-L, IL-4, SCF, and GM-CSF. cDC1, cDC2,
and mono/mac presence in each well was
analyzed by flow cytometry. Bars represent the
percentage of wells that contained each of the
indicated populations irrespective of the presence
or absence of any others. The actual number of
wells is indicated on top of each bar. Data are a
pool of four independent experiments.
(B) Bar graph showing the percentage of single
progenitors producing only cDC1 cells (pink), only
cDC2 cells (green), or only cDC1 and cDC2 cells
(black). White includes wells that gave rise to other
cell types with or without cDCs. Contour plots
show an example for single GMP or MLP culture
wells containing only cDC1 and cDC2.
(C) cDC1 and cDC2 generation in single-cell cul-
tures. The graphs illustrate the percentage of
cDC1 (top) or%of cDC2 (bottom) detected in each
cDC1- or cDC2-positive well seeded with single
CMPs, MLPs, or GMPs. The data are a pool of four
independent experiments. The lines represent the
mean.
(D) Bar graphs representing the percentage of
IRF-8+ (left) or MPO+ (right) single progenitor cells
among total GAPDH+ cells, as determined by
single-cell qRT-PCR. The actual number of IRF-8+
or MPO+ cells compared with the total number of
GAPDH+ cells is indicated on top of each bar. The
center graph shows the relative expression (RE)
of IRF8 compared with GAPDH for each IRF8-
positive cell. *p < 0.001 represents statistically
significant differences in expression between
GMPs and MLPs (unpaired t test). Data are from
one experiment representative of two independent
experiments.
cells with high potential for cDC genera-
tion that can even give rise to a single
cDC subset (cDC1).
MLP- and CMP-Derived cDC1s Are
Transcriptionally Identical
Although cDC1s are thought to be homo-
geneous, the finding that CD1a+HLA-
DR+CD141+DNGR-1+ cells could be
generated from MLPs (efficiently) or
CMPs (less efficiently) prompted the question of whether they
are the same cells. We therefore carried out a transcriptomic
analysis of MLP- or CMP-derived cDC1s and compared both
profiles with a published dataset of DC subsets and monocyte-
derived DC (MoDCs) generated in vitro from total CD34+ HSCs
or purified from peripheral blood (Balan et al., 2014). We found
that bothMLP- andCMP-derived cDC1s expressed the classical
cDC1 gene signature, which includes, among others, IRF8,
TLR3, CLEC9A, and XCR1 transcripts (Figure 4A; Figure S4).
We could also confirm that MLP- and CMP-derived cDC1 did
not express any of the signature genes of MoDCs or pDCs
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(Figure 4A; Figure S4). We then comparedMLP- or CMP-derived
cDC1s with each other by principal component analysis. This re-
vealed that MLP- and CMP-derived cDC1s clustered tightly
together (Figure 4B) and did not display any statistically signifi-
cant differences in gene expression (data not shown). As ex-
pected, MLP- and CMP-derived cDC1s were closest to cDC1
produced in vitro from CD34+ HSC/progenitors or purified from
human blood (Figure 4B). This was confirmed by unsupervised
hierarchical clustering using the 2% of genes with the most
variable expression (Figure 4C). We conclude that MLP- and
CMP-derived CD141+DNGR-1+ cells are indistinguishable and
represent phenotypically bona fide cDC1s.
DISCUSSION
DCpoiesis is often thought to constitute a branch of myelopoie-
sis. Our study shows that human cDC progenitors are enriched
within the pool of early hematopoietic progenitors, the MLPs,
that gives rise to lymphoid cells. This result mirrors a recent study
in mice that used barcoding to follow in vivo the cellular output of
single LMPPs and found that 50% of the cells were imprinted to-
ward the cDC lineage (Naik et al., 2013). In contrast, another
study has recently identified a human MDP in the CD34+ fraction
of human umbilical cord blood and bonemarrow, consistent with
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Figure 4. MLP- and CMP-Derived cDC1
Transcriptomic Analysis
(A) Heatmap of gene expression values comparing
MLP- and CMP-derived cDC1 populations with
a published dataset (GSE57671) of cord blood
CD34+ cell-derived cDC1s and MoDCs as well as
MoDCs derived from purified blood monocytes
and primary cDC1, cDC2, and pDCs purified from
peripheral blood (Balan et al., 2014). Individual
replicates are shown.
(B) Principal component analysis of all genes ex-
pressed inMLP- and CMP-derived cDC1 cells and
in DC populations described in Balan et al., 2014.
Each dot of the same color corresponds to a
replicate sample.
(C) Hierarchical clustering of triplicate samples
of MLP- and CMP-derived cDC1s and published
dataset of cord blood CD34+ cell-derived cDC1s
and MoDCs as well as MoDCs derived from blood
monocytes and primary blood cDC1s, cDC2s,
and pDCs (Balan et al., 2014). The 2% of genes
with the most variable expression were used for
the analysis.
the classical view that DCs derive from a
myeloid branch-producing progenitors
with increased commitment toward the
DC lineage (Lee et al., 2015). However,
Lee et al. (2015) show that only 13%
of single MDPs are able to generate
both cDCs and monocytes (Lee et al.,
2015). Similarly, in mice, the bi-potential-
ity of single MDPs is found in a small
fraction of cells (Sathe et al., 2014). There-
fore, bi-potent monocyte/cDC progeni-
tors may co-exist with CDPs that derive directly from MLPs
and do not have an MDP ancestor.
In humans, the phenotype of the GMP overlaps partially with
that of DC precursors (Lee et al., 2015; See et al., 2017). The
GMP population is therefore likely to be heterogeneous and
contain a substantial fraction of DC precursors, unlike the CMP
population (Lee et al., 2015), explaining why GMPs appear to
be more efficient than their CMP progenitors at generating
DCs. In contrast, DC progenitors do not overlap in phenotype
with MLPs, and our findings of efficient DC generation by MLPs
cannot be ascribed to a small sub-fraction of contaminating cells
because cDC-generating potential was present in more than
50% of cloneable MLPs. This is consistent with the fact that
around half of all MLPs express IRF8, a transcription factor that
has been shown to auto-activate and trigger cDC1 subset differ-
entiation (Grajales-Reyes et al., 2015) and the loss of which leads
to humanDCdeficiency (Hambleton et al., 2011). Therefore, as in
mice, human DCs appear to have two types of progenitors. One
‘‘late’’ progenitor shared with monocytes (Fogg et al., 2006; Lee
et al., 2015) and one found very early in the hematopoietic tree
at the MLP level (Naik et al., 2013). Which of these progenitors
contributes most to the steady-state pool of cDCs is unknown.
These results, suggesting a dual ontogeny of cDCs, led us to
ask whether cDC1 cells deriving from distinct developmental
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pathways are equivalent. The latter would indicate an overriding
role of ‘‘nurture’’ in cDC differentiation, whereas the former
would suggest that cellular ‘‘nature’’ leaves an indelible imprint
in progeny at the level of gene expression and, perhaps, func-
tion. Interestingly, we found an exclusive role for nurture in that
MLP-derived and CMP-derived cDC1s possess identical tran-
scriptomes. Because gene expression underlies cell function,
we presume that both sources of cDC1s lead to cells with iden-
tical properties, although we did not perform exhaustive func-
tional analyses. Interestingly, mouse pDCs can also originate
from either myelo- or lymphopoietic branches and are seemingly
identical, other than displaying or not displaying a history of
recombination activating gene (RAG) expression (Sathe et al.,
2013; Shortman et al., 2013). Whether distinct pathways of DC
production prevail in different settings remains to be explored,
as does the possibility that, under some circumstances, cDCs
derived from MLPs and those derived from MDPs may acquire
different functional properties.
EXPERIMENTAL PROCEDURES
Mice
NOD/SCID/IL-2Rg-null mice transgenic for human SCF, IL3, and GM-CSF
(NSG-SGM3) were bred at the Francis Crick Institute under specific path-
ogen-free conditions. Age- and sex-matched mice were used for all experi-
ments. All experiments were performed in accordance with national and insti-
tutional guidelines for animal care and were approved by the Francis Crick
Institute Animal Ethics Committee and by the United Kingdom Home Office.
Human Cells
Umbilical cord blood from healthy neonates was obtained from the Anthony
Nolan Cell Therapy Centre under an agreement that includes ethical approval
for laboratory research use. Mononuclear cells were obtained by density
centrifugation using Ficoll-Paque (GE Healthcare) and ammonium chloride
red cell lysis.
Flow Cytometry Analysis
Cells were stained in ice-cold PBS containing fetal calf serum (FCS, 2%) and
EDTA (2 mM) using appropriate antibody-fluorophore conjugates. Prior to
staining for DNGR-1, cells were pre-incubated on ice with mouse serum (Jack-
son ImmunoResearch Laboratories) and purified immunoglobulin G2a (IgG2a,
BioLegend) to block Fc receptors. See the Supplemental Experimental Pro-
cedures for antibodies used. Multiparameter acquisition was performed on a
Fortessa analyzer (BD Biosciences), and data were analyzed with FlowJo soft-
ware (Tree Star). Prior to acquisition, cells were resuspended in PBS/FCS and
2%/EDTA (2 mM) solution with 1 mg/ml of DAPI to exclude dead cells.
Cell Sorting
Cells were sorted on a BD FACS Aria (BD Biosciences). For sorting of
progenitors, mononuclear cells were isolated from umbilical cord blood,
and lineage-negative cells were enriched using magnetic beads. Briefly, cells
were incubated with Fc-block (BD Biosciences) for 10 min, stained with fluo-
rescein isothiocyanate (FITC)-conjugated antibodies against lineage markers
(Lin1-FITC) and washed before incubation with anti-FITC beads and enrich-
ment on LD columns (both from Miltenyi Biotec). The flow-through fraction
was stained with antibodies and sorted by FACS to achieve 99% purity.
Dead cells were excluded using DAPI.
In Vitro Cultures
500–2,000 purified progenitors were cultured for 12 days in Iscove’s Modified
Dulbecco’s Medium (IMDM) culture medium (Gibco) supplemented with
b-mercaptoethanol and 10% heat-inactivated FCS at 37C, together with
the following cytokines (R&D Systems): human fms-like tyrosine kinase 3
ligand (hFLT3L) (100 ng/mL), human stem cell factor (hSCF) (20 ng/mL), human
interleukin-4 (hIL-4) (20 ng/mL), and human granulocyte-macrophage colony-
stimulating factor (hGM-CSF) (20 ng/mL). Half of the medium containing the
cytokine cocktail was replaced every 3 days. In single-cell culture experi-
ments, MS5 mouse fibroblast feeder cells were seeded in 96 well-culture
plates (flat bottom) the day before to achieve 60%–70% confluence (3,000
MS5 cells/well). Single progenitors were then sorted directly onto the MS5
cell layer, and medium with cytokines was added subsequently.
In Vivo Transfer
Mice ages 8–12 weeks were sub-lethally irradiated (2 Gy) up to 24 hr before
intravenous (i.v.) injection of 5,000–10,000 sorted CMPs, MLPs, or GMPs.
The bone marrow of reconstituted mice was analyzed 2 weeks later.
Single-Cell qPCR
Single MLPs, CMPs, or GMPs were sorted directly into dry 96-well PCR plates
and frozen at 80C. See the Supplemental Experimental Procedures for
cDNA production. qPCR for IRF8, MPO, and GAPDHwas performedwith Taq-
Man Universal PCRMasterMix (Applied Biosystems) and predesigned primers
and probe mixes (TaqMan gene expression assays, Applied Biosystems).
Measurementswere performed using a sequence detection system (ABI Prism
7700, Applied Biosystems). The levels of mRNA for the specific gene being
measured were divided by those for GAPDH measured in parallel (normalized
expression).
Microarrays
CD141+DNGR-1+ cDC1 cells were sorted according to the gating strategy de-
picted in Figure 1B (upper panels) to achieve 99% purity. For each population,
total RNA was extracted using an RNeasy Micro- or Minikit (QIAGEN). RNA
was hybridized to the Affymetrix Human Gene 2.0 ST array according to the
manufacturer’s instructions. Each analysis was performed in triplicate using
independently sorted cells from independent cultures. See the Supplemental
Experimental Procedures for the microarray analysis.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism as indicated in the
figure legends. For the microarray analysis, differentially expressed genes
were assessed using an empirical Bayes t test. The p values were adjusted
using the Benjamini-Hochberg method. Microarrays data from a previous
study used for comparative analysis are available under accession number
GEO: GSE57671.
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO:
GSE98957.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2017.06.075.
AUTHOR CONTRIBUTIONS
Conceptualization, J.H., C.R.S., F.A.A., and D.B.; Methodology, J.H., C.R.S.,
F.A.A., and D.B.; Investigation, J.H., F.A.A., and A.G.v.d.V.; Formal Analysis,
J.H., C.R.S., and P.C.; Writing – Original Draft, J.H. and C.R.S.; Writing – Re-
view & Editing, J.H. and C.R.S.; Visualization, J.H.; Supervision, C.R.S.; Proj-
ect Administration, J.H.; Funding Acquisition, C.R.S.
ACKNOWLEDGMENTS
We thank the Francis Crick Institute FACS laboratory for technical help. We are
grateful to all members of the Immunobiology Laboratory and the Haemato-
poietic Stem Cell Laboratory for helpful discussions and comments. We thank
Irene Sanjuan-Nandin from the Lymphocyte Biology Laboratory for advice and
Cell Reports 20, 529–537, July 18, 2017 535
Pierre Guermonprez for critical reading of the manuscript. This work was sup-
ported by the Francis Crick Institute, which receives core funding from Cancer
Research UK (FC001136 and FC001045), the UK Medical Research Council
(FC001136 and FC001045), and the Wellcome Trust (FC001136 and
FC001045) and by ERC Advanced Investigator Grant AdG 268670 (to C.R.S.).
Received: February 18, 2017
Revised: May 22, 2017
Accepted: June 23, 2017
Published: July 18, 2017
REFERENCES
Akashi, K., Traver, D., Miyamoto, T., and Weissman, I.L. (2000). A clonogenic
commonmyeloid progenitor that gives rise to all myeloid lineages. Nature 404,
193–197.
Aliberti, J., Schulz, O., Pennington, D.J., Tsujimura, H., Reis e Sousa, C.,
Ozato, K., and Sher, A. (2003). Essential role for ICSBP in the in vivo develop-
ment of murine CD8alpha + dendritic cells. Blood 101, 305–310.
Balan, S., Ollion, V., Colletti, N., Chelbi, R., Montanana-Sanchis, F., Liu, H., Vu
Manh, T.P., Sanchez, C., Savoret, J., Perrot, I., et al. (2014). Human XCR1+
dendritic cells derived in vitro from CD34+ progenitors closely resemble blood
dendritic cells, including their adjuvant responsiveness, contrary tomonocyte-
derived dendritic cells. J. Immunol. 193, 1622–1635.
Billerbeck, E., Barry, W.T., Mu, K., Dorner, M., Rice, C.M., and Ploss, A. (2011).
Development of human CD4+FoxP3+ regulatory T cells in human stem cell
factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-
3-expressing NOD-SCID IL2Rg(null) humanized mice. Blood 117, 3076–3086.
Breton, G., Lee, J., Zhou, Y.J., Schreiber, J.J., Keler, T., Puhr, S., Anandasa-
bapathy, N., Schlesinger, S., Caskey, M., Liu, K., and Nussenzweig, M.C.
(2015). Circulating precursors of human CD1c+ and CD141+ dendritic cells.
J. Exp. Med. 212, 401–413.
Caux, C., Vanbervliet, B., Massacrier, C., Dezutter-Dambuyant, C., de Saint-
Vis, B., Jacquet, C., Yoneda, K., Imamura, S., Schmitt, D., and Banchereau,
J. (1996). CD34+ hematopoietic progenitors from human cord blood differ-
entiate along two independent dendritic cell pathways in response to GM-
CSF+TNF alpha. J. Exp. Med. 184, 695–706.
Chicha, L., Jarrossay, D., and Manz, M.G. (2004). Clonal type I interferon-pro-
ducing and dendritic cell precursors are contained in both human lymphoid
and myeloid progenitor populations. J. Exp. Med. 200, 1519–1524.
Crozat, K., Guiton, R., Contreras, V., Feuillet, V., Dutertre, C.A., Ventre, E., Vu
Manh, T.P., Baranek, T., Storset, A.K., Marvel, J., et al. (2010). The XC chemo-
kine receptor 1 is a conserved selective marker of mammalian cells homolo-
gous to mouse CD8alpha+ dendritic cells. J. Exp. Med. 207, 1283–1292.
D’Amico, A., and Wu, L. (2003). The early progenitors of mouse dendritic cells
and plasmacytoid predendritic cells are within the bone marrow hemopoietic
precursors expressing Flt3. J. Exp. Med. 198, 293–303.
Doulatov, S., Notta, F., Eppert, K., Nguyen, L.T., Ohashi, P.S., and Dick, J.E.
(2010). Revised map of the human progenitor hierarchy shows the origin of
macrophages and dendritic cells in early lymphoid development. Nat. Immu-
nol. 11, 585–593.
Fogg, D.K., Sibon, C., Miled, C., Jung, S., Aucouturier, P., Littman, D.R.,
Cumano, A., and Geissmann, F. (2006). A clonogenic bone marrow progenitor
specific for macrophages and dendritic cells. Science 311, 83–87.
Ginhoux, F., Liu, K., Helft, J., Bogunovic, M., Greter, M., Hashimoto, D., Price,
J., Yin, N., Bromberg, J., Lira, S.A., et al. (2009). The origin and development of
nonlymphoid tissue CD103+ DCs. J. Exp. Med. 206, 3115–3130.
Grajales-Reyes, G.E., Iwata, A., Albring, J., Wu, X., Tussiwand, R., Kc, W.,
Kretzer, N.M., Brisen˜o, C.G., Durai, V., Bagadia, P., et al. (2015). Batf3 main-
tains autoactivation of Irf8 for commitment of a CD8a(+) conventional DC clo-
nogenic progenitor. Nat. Immunol. 16, 708–717.
Greter, M., Helft, J., Chow, A., Hashimoto, D., Mortha, A., Agudo-Cantero, J.,
Bogunovic, M., Gautier, E.L., Miller, J., Leboeuf, M., et al. (2012). GM-CSF
controls nonlymphoid tissue dendritic cell homeostasis but is dispensable
for the differentiation of inflammatory dendritic cells. Immunity 36, 1031–1046.
Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S.H., Onai, N., Schraml, B.U.,
Segura, E., Tussiwand, R., and Yona, S. (2014). Dendritic cells, monocytes and
macrophages: a unified nomenclature based on ontogeny. Nat. Rev. Immunol.
14, 571–578.
Hambleton, S., Salem, S., Bustamante, J., Bigley, V., Boisson-Dupuis, S.,
Azevedo, J., Fortin, A., Haniffa, M., Ceron-Gutierrez, L., Bacon, C.M., et al.
(2011). IRF8 mutations and human dendritic-cell immunodeficiency. N. Engl.
J. Med. 365, 127–138.
Hildner, K., Edelson, B.T., Purtha, W.E., Diamond, M., Matsushita, H.,
Kohyama, M., Calderon, B., Schraml, B.U., Unanue, E.R., Diamond, M.S.,
et al. (2008). Batf3 deficiency reveals a critical role for CD8alpha+ dendritic
cells in cytotoxic T cell immunity. Science 322, 1097–1100.
Karsunky, H., Merad, M., Cozzio, A., Weissman, I.L., and Manz, M.G. (2003).
Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and
myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J. Exp. Med.
198, 305–313.
Kondo, M., Weissman, I.L., and Akashi, K. (1997). Identification of clonogenic
common lymphoid progenitors in mouse bone marrow. Cell 91, 661–672.
Lee, J., Breton, G., Oliveira, T.Y., Zhou, Y.J., Aljoufi, A., Puhr, S., Cameron,
M.J., Se´kaly, R.P., Nussenzweig, M.C., and Liu, K. (2015). Restricted dendritic
cell and monocyte progenitors in human cord blood and bone marrow. J. Exp.
Med. 212, 385–399.
Liu, K., Victora, G.D., Schwickert, T.A., Guermonprez, P., Meredith, M.M., Yao,
K., Chu, F.F., Randolph, G.J., Rudensky, A.Y., and Nussenzweig, M. (2009).
In vivo analysis of dendritic cell development and homeostasis. Science
324, 392–397.
Manz, M.G., Traver, D., Akashi, K., Merad, M., Miyamoto, T., Engleman, E.G.,
and Weissman, I.L. (2001). Dendritic cell development from common myeloid
progenitors. Ann. N.Y. Acad. Sci. 938, 167–173, discussion 173–174.
McGovern, N., Schlitzer, A., Gunawan, M., Jardine, L., Shin, A., Poyner, E.,
Green, K., Dickinson, R., Wang, X.N., Low, D., et al. (2014). Human dermal
CD14+ cells are a transient population of monocyte-derived macrophages.
Immunity 41, 465–477.
McKenna, H.J., Stocking, K.L., Miller, R.E., Brasel, K., De Smedt, T., Maras-
kovsky, E., Maliszewski, C.R., Lynch, D.H., Smith, J., Pulendran, B., et al.
(2000). Mice lacking flt3 ligand have deficient hematopoiesis affecting
hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood
95, 3489–3497.
Merad, M., Sathe, P., Helft, J., Miller, J., and Mortha, A. (2013). The dendritic
cell lineage: ontogeny and function of dendritic cells and their subsets in the
steady state and the inflamed setting. Annu. Rev. Immunol. 31, 563–604.
Murphy, T.L., Grajales-Reyes, G.E., Wu, X., Tussiwand, R., Brisen˜o, C.G.,
Iwata, A., Kretzer, N.M., Durai, V., and Murphy, K.M. (2016). Transcriptional
Control of Dendritic Cell Development. Annu. Rev. Immunol. 34, 93–119.
Naik, S.H., Sathe, P., Park, H.Y., Metcalf, D., Proietto, A.I., Dakic, A., Carotta,
S., O’Keeffe, M., Bahlo, M., Papenfuss, A., et al. (2007). Development of plas-
macytoid and conventional dendritic cell subtypes from single precursor cells
derived in vitro and in vivo. Nat. Immunol. 8, 1217–1226.
Naik, S.H., Perie´, L., Swart, E., Gerlach, C., van Rooij, N., de Boer, R.J., and
Schumacher, T.N. (2013). Diverse and heritable lineage imprinting of early
haematopoietic progenitors. Nature 496, 229–232.
Onai, N., Obata-Onai, A., Schmid, M.A., Ohteki, T., Jarrossay, D., and Manz,
M.G. (2007). Identification of clonogenic common Flt3+M-CSFR+ plasmacy-
toid and conventional dendritic cell progenitors in mouse bone marrow. Nat.
Immunol. 8, 1207–1216.
Persson, E.K., Uronen-Hansson, H., Semmrich, M., Rivollier, A., Ha¨gerbrand,
K., Marsal, J., Gudjonsson, S., Ha˚kansson, U., Reizis, B., Kotarsky, K., and
Agace, W.W. (2013). IRF4 transcription-factor-dependent CD103(+)CD11b(+)
dendritic cells drive mucosal T helper 17 cell differentiation. Immunity 38,
958–969.
536 Cell Reports 20, 529–537, July 18, 2017
Poulin, L.F., Salio, M., Griessinger, E., Anjos-Afonso, F., Craciun, L., Chen,
J.L., Keller, A.M., Joffre, O., Zelenay, S., Nye, E., et al. (2010). Characterization
of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse
CD8alpha+ dendritic cells. J. Exp. Med. 207, 1261–1271.
Poulin, L.F., Reyal, Y., Uronen-Hansson, H., Schraml, B.U., Sancho, D., Mur-
phy, K.M., Ha˚kansson, U.K., Moita, L.F., Agace, W.W., Bonnet, D., and Reis e
Sousa, C. (2012). DNGR-1 is a specific and universal marker of mouse and hu-
man Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues.
Blood 119, 6052–6062.
Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001). Stem cells,
cancer, and cancer stem cells. Nature 414, 105–111.
Sathe, P., Vremec, D., Wu, L., Corcoran, L., and Shortman, K. (2013). Conver-
gent differentiation: myeloid and lymphoid pathways to murine plasmacytoid
dendritic cells. Blood 121, 11–19.
Sathe, P., Metcalf, D., Vremec, D., Naik, S.H., Langdon, W.Y., Huntington,
N.D.,Wu, L., and Shortman, K. (2014). Lymphoid tissue and plasmacytoid den-
dritic cells and macrophages do not share a common macrophage-dendritic
cell-restricted progenitor. Immunity 41, 104–115.
Schlenner, S.M., Madan, V., Busch, K., Tietz, A., La¨ufle, C., Costa, C., Blum,
C., Fehling, H.J., and Rodewald, H.R. (2010). Fate mapping reveals separate
origins of T cells and myeloid lineages in the thymus. Immunity 32, 426–436.
Schlitzer, A., McGovern, N., Teo, P., Zelante, T., Atarashi, K., Low, D., Ho,
A.W., See, P., Shin, A., Wasan, P.S., et al. (2013). IRF4 transcription factor-
dependent CD11b+ dendritic cells in human and mouse control mucosal IL-
17 cytokine responses. Immunity 38, 970–983.
See, P., Dutertre, C.A., Chen, J., G€unther, P., McGovern, N., Irac, S.E., Guna-
wan, M., Beyer, M., Ha¨ndler, K., Duan, K., et al. (2017). Mapping the human DC
lineage through the integration of high-dimensional techniques. Science 356,
eaag3009.
Shortman, K., Sathe, P., Vremec, D., Naik, S., and O’Keeffe, M. (2013). Plas-
macytoid dendritic cell development. Adv. Immunol. 120, 105–126.
Steinman, R.M., Hawiger, D., Liu, K., Bonifaz, L., Bonnyay, D., Mahnke, K.,
Iyoda, T., Ravetch, J., Dhodapkar, M., Inaba, K., and Nussenzweig, M.
(2003). Dendritic cell function in vivo during the steady state: a role in peripheral
tolerance. Ann. N Y Acad. Sci. 987, 15–25.
Traver, D., Akashi, K., Manz, M., Merad, M., Miyamoto, T., Engleman, E.G.,
and Weissman, I.L. (2000). Development of CD8alpha-positive dendritic cells
from a common myeloid progenitor. Science 290, 2152–2154.
Tussiwand, R., Everts, B., Grajales-Reyes, G.E., Kretzer, N.M., Iwata, A.,
Bagaitkar, J., Wu, X., Wong, R., Anderson, D.A., Murphy, T.L., et al. (2015).
Klf4 expression in conventional dendritic cells is required for T helper 2 cell
responses. Immunity 42, 916–928.
Villani, A.C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K., Fletcher, J.,
Griesbeck, M., Butler, A., Zheng, S., Lazo, S., et al. (2017). Single-cell RNA-
seq reveals new types of human blood dendritic cells, monocytes, and pro-
genitors. Science 356, eaah4573.
Cell Reports 20, 529–537, July 18, 2017 537
